U.S. Machinery Stock News

Burlington Stores (BURL) has posted its Q3 2026 results, reporting revenue of $2.7 billion and net income of $104.8 million, with EPS coming in at $1.66. The company has seen revenue climb from $2.5 billion in Q3 2025, while trailing twelve month revenue now stands at $11.2 billion, up from $10.5 billion a year earlier. Margins have held firm, setting the stage for investors to evaluate how the fresh numbers inform or challenge existing growth stories on BURL. See our full analysis for...

Wondering if TaskUs is undervalued or ready for its next move? You are not alone, as plenty of investors are looking for signals beneath the recent headlines. The stock rose 3.7% in the last week, but has slipped by 20.5% over the past month and is down 32.7% year-to-date. These figures suggest shifting sentiment and risk perceptions around the business. Recently, TaskUs captured attention when it announced a new outsourcing partnership with a major client. This development has piqued...

Zoom Communications (ZM) just posted its Q3 2026 results, reporting revenue of $1.2 billion and basic EPS of $2.05. Over the past year, the company has seen revenue climb from $4.6 billion to $4.8 billion, with EPS rising from $2.86 to $5.26. Margins leaned stronger this quarter, reflecting both the boost from a one-off gain and robust operational execution. See our full analysis for Zoom Communications. Let’s see how these results compare to the popular narratives circulating in the...

Alibaba Group Holding (NYSE:BABA) just released its Q2 2026 results, reporting revenue of ¥247.8 billion and basic EPS of ¥9.05. Looking over the past year, the company has seen revenue climb from ¥961.9 billion ($129.2 billion) to ¥1,012.1 billion ($135.6 billion), while EPS rose from ¥35.22 to ¥54.10. This reflects notable momentum in recent quarters. Margins have expanded and profit growth has accelerated, positioning the results as a strong talking point for shareholders. See our full...

Senstar Technologies (SNT) has just reported its Q3 2025 results, posting revenue of $9.5 million and basic EPS of $0.043. Looking at recent trends, the company has seen revenue move from $8.3 million in Q2 2024 to $10.2 million in Q4 2024 before settling at $9.5 million this quarter. Basic EPS over the same period shifted from $0.021 to $0.068 and now $0.043. These results came alongside firm profit margins, setting the tone for how investors may interpret the quality of earnings this...

DICK'S Sporting Goods (DKS) has just reported Q3 2026 results with revenue reaching $4.2 billion and net income at $75.2 million, resulting in a quarterly EPS of $0.88. The company has seen revenue increase from $3.1 billion in Q3 2025 to $4.2 billion in Q3 2026, with same store sales growth of 5.7% over the latest quarter. However, margins have tightened compared to last year, adding a note of caution to what investors might otherwise view as a strong set of headline numbers. See our full...

Ever wondered if Exelon stock lives up to its buzz, or if the current price actually offers value? You are not alone. Investors are watching closely to decide if now is the right moment to get in or hold back. Stocks do not move for no reason. Exelon certainly caught attention with a 2.2% gain in the last week, helping power an impressive 23.7% year-to-date climb and a striking 87.5% surge over the past five years. That momentum did not appear out of thin air. Recent sector-wide optimism and...

Thinking about whether Nebius Group is fairly priced? Let’s take a closer look at what has been driving interest, as well as what could matter for investors evaluating the stock’s value. The stock has kept traders active, with a recent 24.5% slide over the past month. Despite this, it remains up 210.4% year-to-date and 341.9% over the past 12 months. There has been ongoing news about Nebius Group’s ambitious product expansion plans and growing partnerships, capturing the attention of both...

Gaotu Techedu (NYSE:GOTU) just released its Q3 2025 results, recording revenue of ¥1.6 billion and a basic EPS of -¥0.61. For context, the company’s revenue has climbed from ¥1.0 billion in Q2 2024 to ¥1.6 billion this quarter. Basic EPS has improved from -¥1.65 in Q2 2024. Investors will be watching how the company works to narrow its losses and maintain the current pace of revenue growth as margins remain in focus this quarter. See our full analysis for Gaotu Techedu. Now that the headline...

Petco Health and Wellness Company (WOOF) just reported Q3 2026 financials, posting revenue of $1.5 billion and basic EPS of $0.03. Over the past year, the company has seen revenue move from $6.2 billion to $6.0 billion with EPS tracking from -$4.95 to -$0.01, highlighting recent volatility in earnings. Margins remain under pressure, keeping the conversation tightly focused on the company’s path toward profitability. See our full analysis for Petco Health and Wellness Company. Next, we will...

Atour Lifestyle Holdings (NasdaqGS:ATAT) just released its Q3 2025 results, reporting revenue of ¥2.6 billion and basic EPS of ¥3.41. Over the past year, the company has seen revenue climb from ¥6.1 billion to ¥9.1 billion, up 20.4%, while EPS increased from ¥7.57 to ¥10.62, a 26.2% gain. Although net profit margins narrowed slightly compared to last year, the topline and EPS growth indicate the business is still delivering for shareholders. See our full analysis for Atour Lifestyle...

Thinking about whether CBRE Group offers real value right now? You are not alone, as more investors are questioning if the impressive run can last or if the stock has become too expensive. CBRE Group has shown strong performance lately, climbing 6.9% in just the past week, up 24.9% year-to-date, and delivering a massive 162.3% over the last 5 years. Market enthusiasm for CBRE Group has been fueled by a string of headline deals and sector momentum, including increased activity in commercial...

Jiayin Group (NasdaqGM:JFIN) posted total revenue of ¥1.47 billion and basic EPS of ¥7.34 for the third quarter of 2025, accompanied by a net income of ¥376.49 million. The company has seen revenue move from ¥1.44 billion in Q3 2024 to ¥1.47 billion in Q3 2025, while EPS climbed from ¥5.07 to ¥7.34 over the same period. These results point to expanding margins and a favorable profit backdrop heading into the next reporting cycle. See our full analysis for Jiayin Group. Next up, we’re...

Safe Bulkers (SB) has just released its Q3 2025 results, reporting total revenue of $73.1 million and basic EPS of $0.15, with net income of $15.8 million for the quarter. The company has seen revenue fluctuate over the past several quarters, decreasing from $78.5 million in Q2 2024 to a low of $64.3 million in Q1 2025 before rebounding this quarter. EPS also moved from $0.24 in Q2 2024 to a modest loss in Q2 2025, before returning to positive territory. Margins have compressed over the last...

Dell Technologies (DELL) just published its Q3 2026 results, posting revenue of $27.0 billion and basic EPS of $2.28. The company has seen revenue trend from $24.4 billion in Q3 last year to over $29.8 billion in Q2 and now $27.0 billion this quarter. EPS has moved from $1.61 a year ago to $2.36 in Q4 and $2.28 now. Solid profit margins and steady earnings trends continue to shape an intriguing picture for investors eyeing Dell's financial momentum. See our full analysis for Dell...

Lucky Strike Entertainment (LUCK) shares moved 3% higher today, catching some attention from investors. While there wasn’t a high-profile catalyst, moves like this often have traders checking for clues about shifting sentiment or potential upcoming announcements. See our latest analysis for Lucky Strike Entertainment. While Lucky Strike Entertainment’s latest 3% jump puts some spark back in the share price, longer-term momentum has been mixed. The 7-day share price return of 8.3% suggests...

In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway. This move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators. We'll explore how securing FDA...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

As the U.S. stock market experiences a notable upswing with major indexes like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing significant gains entering the Thanksgiving holiday, investors are increasingly attentive to opportunities that may be trading below their estimated value. In such a buoyant environment, identifying stocks that are potentially undervalued can provide investors with strategic entry points to capitalize on broader market optimism while maintaining a focus...

As the U.S. stock market continues its upward trajectory, with major indexes marking their biggest weekly rise since June, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, a term that may seem outdated yet remains significant, represent smaller or newer companies that can potentially offer substantial returns when they are built on solid financial foundations. In this article, we will explore three penny stocks that exhibit strong...

As major U.S. stock indices, including the Dow Jones, Nasdaq, and S&P 500, continue to experience gains entering the Thanksgiving holiday week, investors are keenly observing market dynamics that could impact small-cap stocks. With economic indicators showing mixed signals and broader market sentiment fluctuating, identifying promising yet lesser-known stocks becomes crucial for those looking to capitalize on potential opportunities in a dynamic environment.

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics recently announced the initiation of a rolling New Drug Application submission to the U.S. FDA for accelerated approval of zipalertinib, targeting EGFR exon 20 insertion-mutated non-small cell lung cancer after chemotherapy. This milestone builds on zipalertinib’s Breakthrough Therapy Designation and leverages data from the REZILIENT1 Phase 1/2 trial involving previously treated patients. We'll explore how progress toward FDA...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Hanesbrands (HBI) recently posted modest gains, with shares ticking up about 1% over the past week. Investors are weighing the company's mixed fundamentals as the consumer durables sector undergoes shifts and retail demand trends continue to evolve. See our latest analysis for Hanesbrands. Hanesbrands has seen its share price rebound slightly over the past quarter, but momentum remains mixed after a tough year, with a 1-year total shareholder return of -25.11%. While short bursts of optimism...